Novo Nordisk brings forward salary regulations for 50,000 employees due to increasing inflation

As inflation continues to rise, Novo Nordisk has decided to move up next year’s salary changes for the company’s employees.

Lars Frugergaard Jørgensen, CEO of Novo Nordisk | Photo: Stine Bidstrup/ERH

Increasing inflation has made Denmark’s biggest pharmaceutical company, Novo Nordisk, move up its scheduled wage regulations for more than 50,000 employees, according to an internal company message that MedWatch has seen and that the company confirms.

The next round of salary changes will now take place around the New Year instead of April or June next year, when they were actually due for most workers at the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs